Genetically‐Programmed Hypervesiculation of Lactiplantibacillus Plantarum Increases Production of Bacterial Extracellular Vesicles with Therapeutic Efficacy in a Preclinical Inflammatory Bowel Disease Model
Advanced Science · 2026-02 · 13 (8)
DOI: 10.1002/advs.202512679 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 26.11.2025. Verfasst von Nicholas H Pirolli und 16 weiteren Autor:innen. Beteiligte Einrichtung: Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA. Hauptthemen laut MEDLINE: Extracellular Vesicles, Probiotics, Inflammatory Bowel Diseases, Lactiplantibacillus plantarum. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Maryland Innovation Initiative, U.S. Department of Veterans Affairs.
Abstract (Originalsprache)
Inflammatory bowel diseases (IBD) affect over 6 million people globally and current treatments achieve only 10‐20% rates of durable disease remission. Bacterial extracellular vesicles (BEVs) from probiotic lactic acid bacteria (LAB) are a promising novel therapeutic with mechanisms holding potential to drive increased rates of durable disease remission, including immunomodulation and intestinal epithelial tissue repair. However, translation of these cell‐secreted nanovesicles is limited by long standing biomanufacturing hurdles, especially low production yields due to low biogenesis rates from cells. Here, Lactiplantibacillus plantarum is identified as a candidate LAB producing BEVs effective in treating acute dextran sulfate sodium (DSS)‐induced murine colitis with greater efficacy than BEVs from probiotic Escherichia coli Nissle 1917. Genetic engineering of L. plantarum to create a hypervesiculating strain via inducible expression of a peptidoglycan‐modifying enzyme is shown to enable a 66‐fold increase in BEV productivity. Finally, hypervesiculating L. plantarum BEVs are confirmed to be therapeutically effective in the acute DSS mouse model of colitis, with superior reduction of mucosal tissue damage compared to live L. plantarum cells. These findings demonstrate that BEVs from genetically engineered hypervesiculating strain of L. plantarum are a promising preclinical therapeutic candidate for IBD that overcomes historical biomanufacturing limitations of BEV therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
- Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, MD, USA.
- Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD, USA.
- Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, USA.
- Biomedical Laboratory Research and Development Service, Veterans Affairs Maryland Healthcare System, Baltimore, MD, USA.
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, MD, USA.
ORCID-Profile: Steven M Jay
Förderung
- NHLBI NIH HHS
- Maryland Innovation Initiative
- U.S. Department of Veterans Affairs
- NIH HHS
- FDA HHS
- NCATS NIH HHS
- NIDDK NIH HHS
- BLRD VA
Zitieren
APA
Pirolli, N. H., Levy, D., Schledwitz, A., Moura, N. S., Sarkar, M., Solomon, T. J., Powsner, E. H., Nowak, R., Mamczarz, Z., Bridgeman, C. J., Khan, S., Hui, A., Anne, N., Reus, L., Bentley, W. E., Raufman, J. P., & Jay, S. M. (2026). Genetically‐Programmed Hypervesiculation of Lactiplantibacillus Plantarum Increases Production of Bacterial Extracellular Vesicles with Therapeutic Efficacy in a Preclinical Inflammatory Bowel Disease Model. Advanced Science, 13(8). https://doi.org/10.1002/advs.202512679
Vancouver
Pirolli NH, Levy D, Schledwitz A, Moura NS, Sarkar M, Solomon TJ, et al. Genetically‐Programmed Hypervesiculation of Lactiplantibacillus Plantarum Increases Production of Bacterial Extracellular Vesicles with Therapeutic Efficacy in a Preclinical Inflammatory Bowel Disease Model. Advanced Science. 2026;13(8). doi:10.1002/advs.202512679
BibTeX
@article{Pirolli2026,
author = {Pirolli, Nicholas H and Levy, Daniel and Schledwitz, Alyssa and Moura, Natalia Sampaio and Sarkar, Mitali and Solomon, Talia J and Powsner, Emily H and Nowak, Raith and Mamczarz, Zuzanna and Bridgeman, Christopher J and Khan, Sulayman and Hui, Andrew and Anne, Nidhi and Reus, Laura and Bentley, William E and Raufman, Jean-Pierre and Jay, Steven M},
title = {Genetically‐Programmed Hypervesiculation of Lactiplantibacillus Plantarum Increases Production of Bacterial Extracellular Vesicles with Therapeutic Efficacy in a Preclinical Inflammatory Bowel Disease Model},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {8},
doi = {10.1002/advs.202512679}
}
EUVIMED